Riverside Capital-backed A.forall completed the acquisition of US generics portfolio of Provepharm.

Riverside Capital-backed A.forall, a pharmaceutical company focused on making affordable medicines, completed the acquisition of US generics portfolio of Provepharm, an independent, international specialty pharmaceutical company. Financial terms were not disclosed. “The investment delivers immediate scale and diversification benefits to A.forall’s US business. It creates cross-selling opportunities with our existing portfolio, strengthens brand recognition and expands our commercial presence in the world’s largest pharmaceutical market," Steen Vangsgaard, A.forall CEO.